Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst

Ovid Therapeutics Inc. (NASDAQ:OVID) – Analysts at Wedbush increased their Q1 2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.15). Wedbush currently has a “Outperform” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.88 EPS.

Several other analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Ovid Therapeutics has an average rating of “Buy” and a consensus target price of $3.20.

Ovid Therapeutics Stock Down 1.4 %

Shares of NASDAQ OVID opened at $0.43 on Monday. Ovid Therapeutics has a 12-month low of $0.42 and a 12-month high of $3.45. The stock has a market cap of $30.81 million, a PE ratio of -0.92 and a beta of 0.29. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average of $0.65 and a 200 day moving average of $0.95.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.19 million.

Institutional Trading of Ovid Therapeutics

Several hedge funds have recently made changes to their positions in OVID. SG Americas Securities LLC grew its stake in shares of Ovid Therapeutics by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after buying an additional 17,172 shares during the period. XTX Topco Ltd lifted its holdings in shares of Ovid Therapeutics by 46.2% in the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after acquiring an additional 12,076 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares during the last quarter. FMR LLC lifted its holdings in shares of Ovid Therapeutics by 1,907.4% in the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after acquiring an additional 47,723 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in shares of Ovid Therapeutics in the 4th quarter worth approximately $65,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.